About Intensity Therapeutics, Inc.
https://www.intensitytherapeutics.comIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers.
CEO
Lewis H. Bender
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
SAPIENT CAPITAL LLC
Shares:976.8K
Value:$415.14K
SENTINUS, LLC
Shares:481.18K
Value:$204.5K
GEODE CAPITAL MANAGEMENT, LLC
Shares:258.89K
Value:$110.03K
Summary
Showing Top 3 of 29
About Intensity Therapeutics, Inc.
https://www.intensitytherapeutics.comIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.73M ▲ | $-2.67M ▼ | 0% | $-0.06 ▲ | $62K ▲ |
| Q2-2025 | $0 | $2.71M ▼ | $-2.54M ▲ | 0% | $-0.13 ▲ | $-2.71M ▲ |
| Q1-2025 | $0 | $3.39M ▲ | $-3.35M ▼ | 0% | $-0.22 | $-3.39M ▼ |
| Q4-2024 | $0 | $3.2M ▼ | $-3.18M ▲ | 0% | $-0.22 ▲ | $-3.18M ▲ |
| Q3-2024 | $0 | $3.57M | $-3.51M | 0% | $-0.25 | $-3.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.07M ▲ | $9.59M ▲ | $2.36M ▲ | $7.22M ▲ |
| Q2-2025 | $2.22M ▲ | $4.44M ▲ | $2.26M ▼ | $2.18M ▲ |
| Q1-2025 | $929K ▼ | $3.06M ▼ | $2.73M ▲ | $334K ▼ |
| Q4-2024 | $2.59M ▼ | $4.78M ▼ | $1.86M ▼ | $2.92M ▲ |
| Q3-2024 | $2.78M | $5.21M | $2.43M | $2.78M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.67M ▼ | $-2.39M ▲ | $0 | $7.24M ▲ | $4.85M ▲ | $-2.39M ▲ |
| Q2-2025 | $-2.54M ▲ | $-2.46M ▼ | $0 | $3.74M ▲ | $1.29M ▲ | $-2.46M ▼ |
| Q1-2025 | $-3.35M ▼ | $-1.99M ▲ | $0 | $328K ▼ | $-1.66M ▼ | $-1.99M ▲ |
| Q4-2024 | $-3.18M ▲ | $-2.67M ▲ | $0 ▼ | $2.48M ▲ | $-192K ▲ | $-2.67M ▲ |
| Q3-2024 | $-3.51M | $-3.97M | $3.1M | $413K | $-459K | $-3.97M |
CEO
Lewis H. Bender
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
SAPIENT CAPITAL LLC
Shares:976.8K
Value:$415.14K
SENTINUS, LLC
Shares:481.18K
Value:$204.5K
GEODE CAPITAL MANAGEMENT, LLC
Shares:258.89K
Value:$110.03K
Summary
Showing Top 3 of 29